Intraoperative solid-state based urethral dosimetry in low dose rate prostate brachytherapy by Cutajar, Dean et al.
University of Wollongong 
Research Online 
Faculty of Engineering - Papers (Archive) Faculty of Engineering and Information Sciences 
2006 
Intraoperative solid-state based urethral dosimetry in low dose rate 
prostate brachytherapy 
Dean Cutajar 
University of Wollongong, deanc@uow.edu.au 
G. J. Takacs 
University of Wollongong, gjt@uow.edu.au 
M. L. Lerch 
University of Wollongong, mlerch@uow.edu.au 
T. Braddock 
University of Wollongong, braddock@uow.edu.au 
J. A. Bucci 
St George Cancer Care Centre, Australia 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/engpapers 
 Part of the Engineering Commons 
https://ro.uow.edu.au/engpapers/309 
Recommended Citation 
Cutajar, Dean; Takacs, G. J.; Lerch, M. L.; Braddock, T.; Bucci, J. A.; Brady, J.; Duggan, L. J.; Enari, K. E.; 
Zaider, M.; Zelefsky, M.; and Rosenfeld, Anatoly B.: Intraoperative solid-state based urethral dosimetry in 
low dose rate prostate brachytherapy 2006. 
https://ro.uow.edu.au/engpapers/309 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Authors 
Dean Cutajar, G. J. Takacs, M. L. Lerch, T. Braddock, J. A. Bucci, J. Brady, L. J. Duggan, K. E. Enari, M. 
Zaider, M. Zelefsky, and Anatoly B. Rosenfeld 
This journal article is available at Research Online: https://ro.uow.edu.au/engpapers/309 
1408 IEEE TRANSACTIONS ON NUCLEAR SCIENCE, VOL. 53, NO. 3, JUNE 2006
Intraoperative Solid-State Based Urethral Dosimetry
in Low Dose Rate Prostate Brachytherapy
D. L. Cutajar, Member, IEEE, G. J. Takacs, M. L. F. Lerch, Member, IEEE, T. Braddock, J. A. Bucci, J. Brady,
L. J. Duggan, K. E. Enari, M. Zaider, M. Zelefsky, and A. B. Rosenfeld, Senior Member, IEEE
Abstract—This paper presents in phantom testing of a recently
developed intraoperative minidosimetry system, designed to
measure the dose along the urethra during low dose rate prostate
brachytherapy. This system is based on a silicon minidetector and
uses spectroscopy to calculate the localized dose from the treat-
ment radiation. The minidosimetry system was demonstrated to
be operational at body temperature, with a near isotropic response
to radiation at all angles. Phantom measurements have shown the
minidosimetry system to measure the dose from multiple seeds
to within 5% of planning system calculated doses. This system
is an ideal complement to ultrasound guided seed placement in
providing online direct dosimetry during seed implantation, as
well as providing dose planning system verification through post
implant dosimetry.
Index Terms—Brachytherapy, dosimetry, spectroscopy.
I. INTRODUCTION
LOW dose rate brachytherapy through transperineal place-ment of I and Pd based seeds is a common treatment
modality for early stage prostate cancer [1]. The precision of
transrectal ultrasound guided localization of the guiding nee-
dles, as well as an increase in the sophistication of computer-
ized treatment planning has lead to an increase in the popularity
of this modality [2]. Quality assurance is performed postimplant
through dosimetric evaluations, where the source placement rel-
ative to the prostate is obtained, using CT to identify the seed
positions [3].
Medical complications, specifically acute urinary side effects
[4], can arise from interstitial prostate brachytherapy due to er-
rors in seed placement. Several factors may lead to the mis-
placement of seeds throughout the treatment. During implanta-
tion, the guiding needles may diverge as various layers of tissue
are penetrated [5], depositing seeds in an incorrect location; the
seeds may drift out of position due to blood flow; oedema may
alter the size and shape of the prostate; and gland motion may
occur during treatment [6]. Any combination of these factors
may lead to the urethral dose escalating above planned levels.
Wallner et al. [7] observed an increase in grade-3 late urethral
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toxicity for urethral doses exceeding 400 Gy. There is a need
to monitor the urethral dose during implantation to manage ure-
thral toxicity, as well as post implant to verify dose planning.
The American Brachytherapy Society (ABS) has requested the
urethral dose be recorded for correlation with urethral toxicity
[8], recommending the doses be obtained at the center of the
urethra, in half centimeter intervals, measured from the base of
the prostate to the apex. The maximum and mean doses along
the urethra should be specified [8].
We have developed an in vivo minidosimetry system which
may be placed within a Foley catheter for dose measurements
along the urethra, both intraoperative and postimplant. This
system uses a silicon minidetector with an active volume of less
than 1 mm , operating in spectroscopy mode, connected to a
data acquisition system that calculates the dose rate using “spec-
troscopic dosimetry.” Brachytherapy seeds contain radioactive
sources, usually I or Pd. These radioactive sources emit
low energy photons with a distinct energy spectrum, at very low
dose rates, that are impossible to measure with conventional
detectors in confined spaces. Conventional methods of radiation
detection with diodes involve measuring the induced current
with an electrometer. The low dose rates (1–5 cGy/hr) will only
induce current to the order of 0.1 A. At these low energies,
approximately 27 keV for I based seeds, most energy loss
for photons in water/tissue occurs through the photoelectric
effect. The Compton scattering cross-section is significant, but
energy loss due to the Compton effect is minimal. The photon
peaks will be attenuated in intensity. The number of counts in
the photopeaks of a measured spectrum can be related to the
dose rate at the point of measurement. The complexity of the
dosimetry of I and Pd seeds is due to the low dose rates,
anisotropy of dose about the seeds, and rapidly diminishing
dose with distance from the seed. Spectroscopic dosimetry
does not require tissue equivalency of the detector and is very
sensitive as it is based on the registration of single photons.
Theoretical aspects and Monte Carlo simulations justifying the
proposed method can be found in Rosenfeld et al. [9].
In order for this system to be viable, the minidetector needs
to have an isotropic response to radiation from all angles and
needs to produce results in agreement with doses determined by
conventional CT and ultrasound based dose planning systems.
Several in phantom measurements were performed to test the
detector response at various dose rates and the detector isotropy.
These measurements were compared to predicted doses, gener-
ated using VariSeed 7 dose planning software from Varian Med-
ical Systems, Palo Alto, CA. This software uses point source ap-
proximations to accurately predict dose distributions for treat-
0018-9499/$20.00 © 2006 IEEE
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ments involving a large number of seeds. Dose distribution cal-
culations involving a small number of seeds require the seed
dose rate anisotropy to be taken into account. Anisotropy correc-
tions, generated using Monte Carlo simulations and confirmed
using the TG43 protocol [10], were applied to the VariSeed 7
predicted doses for the comparison with the minidosimeter mea-
sured doses.
II. MATERIALS AND METHODS
The urethra minidosimetry probe was constructed using a sil-
icon minidetector inside the tip of a rubber tube of length 30 cm
and diameter 3 mm, connected to a charge sensitive preampli-
fier at the opposite end of the tube. The minidetector was con-
structed from 10 k high resistivity silicon, with a cross sec-
tion of 0.8 2.5 mm and a depletion region of 300 m depth.
The minidetector was designed by the Centre for Medical Ra-
diation Physics and manufactured at SPO-BIT, Kiev, Ukraine.
The design featured an optimized geometry and packaging to
allow for an isotropic response to radiation from all angles and
to provide X-ray spectroscopy at 38 C (to allow for in vivo
measurements). The preamplifier output was connected to a data
acquisition system consisting of a shaping amplifier, adjustable
lower voltage pulse height discriminator, pulse counter, micro-
processor, and LCD display. The pulse height discriminator is
used to set a cutoff between pulses due to photon peaks and
lower level noise, as well as serving as an adjustment for fine
dose rate calibration. Pulses with amplitudes above the discrim-
inator level are sent to the microprocessor for further processing
and determination of the dose rate and extrapolated total deliv-
ered dose in tissue. The microprocessor uses a precalibrated al-
gorithm to calculate the measured dose rate from the number
of counted pulses and the acquisition time. The current dose
rate and expected total dose after full decay are shown on the
LCD display. The minidosimetry system also contains an ana-
logue output from the shaping amplifier to allow connectivity to
an external system, such as an MCA for calibration and quality
assurance testing, or a dose planning system for intraoperative
planning.
A. Calibration
A I based brachytherapy seed, no. 6711 from Amersham
Health, Inc., Princeton, NJ, was placed in a Perspex phantom,
1 cm from the minidosimeter detector. The detector was in line
with the transverse axis of the seed. The expected dose rate was
calculated using the formula [11]
(1)
where is the seed air kerma strength and the specific dose
rate (dose rate in a water per air kerma strength, 1 cm from the
seed on the transverse axis), is the radial dose function, and
is the radial distance from the point of measurement to the seed
Fig. 1. Azimuthal isotropy measurement geometry (solid lines) and polar angle
measurement geometry (dotted lines), where is the azimuthal angle about the
minidosimeter axis and is the polar angle. The horizontal dotted line represents
the location of the catheter within which the seed position was varied for the
polar angle measurements.
center. At 1 cm from the seed on the transverse axis, ,
(1) becomes
(2)
The updated Task Group No. 43 report [10] lists the dose rate
constant, , as 0.965 cGyh mCi , for 6711 seeds with source
strength specified in terms of apparent activity instead
of air kerma. Thus, the dose rate may be calculated using the
formula
(3)
The dose rate algorithm on the minidosimetry system was then
adjusted to output the expected dose rate in water for this seed
measurement.
B. Azimuthal Isotropy Measurements
The isotropy of the response of the detector about the
minidosimeter axis was measured. The minidosimeter probe
was placed in a Perspex phantom, 1 cm from a 6711 seed, on
the transverse axis of the seed. The seed position was rotated
about the axis of the minidosimeter with the dose recorded
every 30 , as shown by Fig. 1.
C. Polar Isotropy Measurements
A gel phantom was constructed to measure the dose rates of
seeds in a 3-D geometry. The phantom contained a straight ar-
tificial urethra for which to place the dosimeter, and allowed
catheters (ProGuide Sharp Needles from Nucletron, Veenen-
daal, Utrecht, The Netherlands [14]) to be inserted parallel to
the urethra, with which seeds could be placed in desired loca-
tions within the phantom. The phantom was filled with a water
based gel.
A catheter was placed in the phantom, 0.5 cm from the ar-
tificial urethra. The total dose expected in a fixed location of
the urethra was measured for a 6711 seed placed in several lo-
cations along the catheter, with each location subtending a dif-
ferent polar angle about the minidosimeter detector and seed, as
shown in Fig. 1. The measured expected total doses were com-
pared to the total doses calculated using VariSeed 7, a treatment
planning system from Varian Medical Systems .
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Fig. 2. Spectrum of a model 6711 seed in Perspex, 1 cm from the minidosimeter
detector. The discriminator level was set at the local minimum below the photo-
peaks of the spectrum, approximately 19 keV. Low level noise and an offset in
the MCA restricted the measurements to pulses greater than 0.5 V amplitude.
D. Depth–Dose Measurements
The total expected dose was measured in the urethra for a
6711 seed in the gel phantom, for various distances between
the seed and the minidosimeter detector, with the detector on
the transverse axis of the seed . The decay-corrected
activity of the seed was calculated to be 0.351 mCi at the time
of measurement. These doses were compared to the total doses
calculated using VariSeed 7.
E. Multiple Seed Measurements
There were 12 seeds, each one model 6711, placed in the
gel phantom about the urethra containing the minidosimeter de-
tector. The decay-corrected activity of each of the seeds was cal-
culated to be 0.351 mCi at the time of measurement. The activity
was assumed to be the same for all seeds as this is acceptable in
practice for seeds from the same batch. The physical characteris-
tics (size, source distribution) were also assumed to be identical.
Four seeds were placed in the same vertical plane as the detector,
in catheters 0.5 cm, 1 cm, 1 cm, and 1.41 cm from the urethra,
running parallel to the urethra. Four seeds were placed in the
above catheters on a vertical plane 1 cm forward of the detector,
and four seeds were placed in the above catheters on a vertical
plane 1 cm beyond the detector. The total expected dose was
measured using the urethral minidosimetry system. The mea-




Fig. 2 shows the energy spectrum from the calibration mea-
surement, recorded on an MCA connected to the shaping am-
plifier analogue output. The lower level discriminator was set
to 1.77 V, allowing only pulses with amplitudes above this to be
counted by the system. The apparent activity of the seed was cal-
culated to be 0.157 mCi, based on the initial activity and elapsed
Fig. 3. Relative dose rate versus Azimuthal angle.
time. From (3), the expected dose rate was calculated to be 0.17
cGyh . The dose rate algorithm on the minidosimetry system
was adjusted to display an output of 0.17 cGyh for the current
measurement. Additionally, fine adjustments may also be made
are also possible with discriminator level changing.
B. Azimuth Isotropy Measurements
Fig. 3 shows the relative dose rate, which is the measured
dose rate normalized to the average, as measured with the
minidosimetry system, of a 6711 seed located 1 cm from the
minidosimeter detector, at various angles about the azimuth of
the minidosimeter probe axis. The minidosimetry system shows
an isotropic response to radiation from all azimuthal angles
within 5%. The discrepancies may be due to the minidetector
not being centered inside the probe, as well as a nonuniform
detector packaging. The zero degree point was arbitrarily
chosen as the detector packaging restricted the determination
of the detector orientation.
C. Polar Isotropy Measurements
The expected total dose from a single seed, at multiple polar
angles to the minidosimeter detector was plotted in Fig. 4 for
both planned and measured doses. The results do not correlate
for doses measured at polar angles 60 and above.
These discrepancies can be seen clearly in Fig. 5, where the
difference between the doses measured with the minidosimetry
system and the VariSeed 7 planned doses, as a percentage, was
plotted against polar angle. Point source approximations were
used by the planning software to calculate the expected doses.
When calculating doses from brachytherapy seeds, seed geom-
etry, and anisotropy should be taken into account [12].
A Monte Carlo simulation was performed using EGSnrc V4
[13]. DOSRZnrc was the code used to simulate the dose in cylin-
drical geometry of a 6711 seed in liquid water. The geometry of
the seed, as shown in Fig. 6, was modeled on the dimensions
used in simulations by Williamson [14].
The results from the simulation were used to generate
anisotropy corrections for the VariSeed 7 planned doses. The
Task Group No. 43 protocol [11] was used to confirm the
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Fig. 4. Expected total dose versus polar angle of measurement for both planned
and experimentally measured doses.
Fig. 5. The difference between the experimentally measured and the planned
doses as a percentage versus polar angle of measurement.
Fig. 6 Model 6711 seed geometry.
anisotropy corrections that were applied to the planned doses.
The measured doses were plotted with the anisotropy corrected
planned doses versus the polar angle in Fig. 7. The difference
between the experimentally measured and the anisotropy cor-
rected planned doses as a percentage versus polar angle of
measurement was plotted in Fig. 8.
Fig. 7. Expected total dose versus polar angle for the measured and anisotropy
corrected planned doses.
Fig. 8. The difference between the experimentally measured and the anisotropy
corrected planned doses as a percentage versus polar angle of measurement.n
After anisotropy correction of the planned doses, the mea-
sured and planned doses have a greater correlation. The discrep-
ancies that still remain may be due to errors in seed placement.
The difficulty in positioning the seeds within the phantom in-
troduced errors in seed localization. The dose decreases rapidly
with distance from the source for low energy photons in water.
Small errors in seed to detector distance can result in large er-
rors in measured dose.
D. Depth–Dose Measurements
Depth–dose measurements were obtained for seeds on the
transverse axis of the minidosimeter detector and
plotted with the VariSeed 7 planned doses in Fig. 9.
The measured doses correspond to the planned doses within
the errors of measurement, including the statistic of counts
during the acquisition time of 10 seconds for seeds placed up
to 2 cm from the minidosimeter detector.
1412 IEEE TRANSACTIONS ON NUCLEAR SCIENCE, VOL. 53, NO. 3, JUNE 2006
Fig. 9. Expected total dose versus distance for measured and VariSeed 7
planned doses.
E. Multiple Seed Measurements
The VariSeed 7 planned dose for the 12-seed configuration
was 79.8 Gy at the point of minidetector of urethral probe in
a phantom. After applying anisotropy corrections for the eight
seeds that were in a different plane to the minidosimeter de-
tector, the corrected planned dose was 73 Gy. The measured ex-
pected total dose was . The measured dose is
within 5% of the planned dose for multiple seed measurements
with anisotropy corrections for the dose planning software.
IV. CONCLUSION
The minidosimetry system has been shown to measure doses
from I based low dose rate brachytherapy seeds to an accu-
racy within 5% of the expected doses for seeds in a 3-D ge-
ometry about the minidosimeter detector, for 0.5 cm to 2 cm
distances. Multiple seed measurements were also accurate to
within 5% of planned doses. Discrepancies in the results may be
attributable to errors in the seed-minidetector localization accu-
racy during the experimental phantom measurements. Localized
doses in brachytherapy are very sensitive to seed position for
seeds within centimeters of the point of measurement due to the
short range of low energy photons in tissue and seed anisotropy.
The minidosimetry system contains a silicon minidetector in-
side a flexible plastic tube, small enough to be placed inside a
Foley catheter for dose measurements along the urethra. The
minidosimetry system may also be adapted to measure the dose
to the rectum wall during low dose rate prostate brachytherapy.
This probe clearly demonstrates the advantage of in vivo ure-
thral dosimetry. While dose planning systems are accurate for
dose prediction along the transverse axis of seeds it is quite es-
sential that anisotropy is accounted for at large polar angles.
This is because most dose planning systems approximate seeds
as point sources. This philosophy is not due to a lack of under-
standing but due to the impossibility of prediction of the polar
angle for particular positions in the prostate when seeds have
been dropped. In case of large distances between seeds and the
point of consideration in the urethra, this error in total dose con-
tribution at this point is negligible, however, in the case of seeds
dropped close to the point of interest in the urethra (less then
0.5 cm) according to the plan, twisting of the seeds can produce
large errors between the planned and real dose.
The minidosimetry system is suitable for intraoperative and
postimplant measurements. The system will complement cur-
rent systems in that the dose profile along the urethra will be
available to practitioners during the procedure. If the dose to the
urethra is exceeding tolerable limits, changes to the plan may be
made in compensation. Postimplant measurements of the ure-
thral dose profile will allow quality assurance of the implant as
well as verification of the plan.
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